Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

OTC Naloxone In US Could Limit Access Due To Costs, Comments On Emergent Switch NDA Argue

Feb 13 2023

• By Malcolm Spicer

• Source: Shutterstock

Related Content

On Emergent OTC Naloxone Switch, Tight Timeline For FDA Decision Following Advisory Committee

Jan 06 2023

Will ACNU Proposal’s Dual Rx/OTC Component Simultaneously Help And Hinder Switches?

Dec 01 2022

US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales

Nov 16 2022

US FDA Expects No Change In Naloxone Access Barrier If Prices High For Potential OTC Products

Aug 30 2022

Additional Topics

International United States FDA Prescription To OTC Switch Drug Approval Standards Advertising, Marketing & Sales Business Strategies Commercial Companies Compliance Consumer Drug Delivery Technology Ingredients Manufacturing Policy Regulation Retail Safety

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window